Module 1: Introduction and Welcome note: Dr Shubhi from Medical Learning Hub welcomed all participants, speakers and the chief guest. She shared details of the webinar and provided general instructions. The first poll was raised.
Module 2: Inaugral address: Dr Kuldeep Sachdeva, Chiefvguest of the CME inaugrated the session describing about thevision about the ManageTB India app and the journey of the development of the app
Module 3: Manage TB India app: Dr Rupak Singla discussed about the ManageTB India app and its features. Outlines of the discussion were:
- Need of ManageTB India application
- Process of app development
- Flow of the app
- Content of the app
- Validation workshops at Delhi and Himachal Pradesh
- Feedbacks of the users
Module 4: Case based discussion on DRTB: Dr Vikas Oswal talked about the management of DRTB in India. Key points of discussion were:
- MDR-TB Regimen Decision
- Gene expert results indicating Rif resistance can lead to labeling the patient as MDR-TB due to the high correlation with Isoniazid resistance.
- Sample sent for first and second LPA and pre-treatment evaluations.
- Shorter Oral BDQ Regimen
- Specific Mutation Considerations
- Resistance patterns guide regimen adjustments, with drugs like Bedaquiline and Levofloxacin being considered.
- Treatment Duration
- Adjustments for Toxicities:
- Adjustments may be made to drug dosages or specific drugs to manage potential toxicities and patient response during the treatment process.
Module 5: Q & A: Several questions were asked from the participants which were all answered by Dr Vikas Oswal and Dr Rupak Singla
Module 6: Vote of thanks: Dr Shubhi from Medical Learning Hub delivered vote of thanks. Second poll was raised.
We wish you a great learning experience!
We thank Mylan Pharmaceuticals Private Limited, a Viatris Company for supporting us in the webinar.
- Inaugural address
- Session 1: Manage TB India app, Dr Rupak Singla
- Q&A
- Session 2: Case based discussion on DRTB, Dr Vikas Oswal
- Q&A
- Vote of thanks
